Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Severe COVID-19 pneumonia in Piacenza, Italy — A cohort study of the first pandemic wave

Lorenzo Guglielmetti a,b,c,*, Irina Kontsevaya d,e,f, Maria C. Leoni c, Patrizia Ferrante c,g, Elisa Fronti c, Laura Gerna c, Caterina Valdatta c, Alessandra Donisi h, Alberto Faggi c, Franco Paolillo c, Giovanna Ratti c, Alessandro Ruggieri c, Marta Scotti c, Daria Sacchini c, Gloria Taliani c,i,j,1, Mauro Codeluppi c,1, For the COVID-Piacenza Group2

* Sorbonne Université, INSERM, U1135, Centre d’Immunologie et des Maladies Infectieuses, Cimi-Paris, équipe 13, Paris, France
1 APHP, Groupe Hospitalier Universitaire Sorbonne Université, Hôpital Pitié-Salpêtrière, Centre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux, Paris, France
2 Infectious Diseases Unit, Piacenza Hospital, Piacenza, Italy
3 Research Center Borstel, Borstel, Germany
4 German Center for Infection Research, Hamburg-Lübeck-Borstel-Riems, Borstel, Germany
5 Institute for Cross-Disciplinary Physics and Complex Systems IFISC (UIB-CSIC), Campus Universitatilles Ballears, E-07122 Palma de Mallorca, Spain
6 Migration Health Unit, Primary Health Care Department, "Guglielmo da Saliceto" Hospital, Piacenza, Italy
7 Infectious and Tropical Disease Unit, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy
8 Anti-COVID Task Force of the Italian Civil Protection

A R T I C L E   I N F O

Article history:
Received 11 August 2020
Received in revised form 13 November 2020
Accepted 18 November 2020

Keywords:
SARS-CoV-2
Coronavirus
Viral pneumonia
Acute respiratory distress syndrome
Mortality

A B S T R A C T

Background: Piacenza is the closest city to the first coronavirus disease 2019 (COVID-19) cluster in Italy and has the highest national COVID-19 death rates per population. The objective of this study is to present characteristics and outcomes of patients admitted to medical departments of the Hospital of Piacenza during the first wave of the epidemic.

Methods: A total of 218 patients with confirmed or suspect COVID-19 and severe pneumonia were included from February 21st to May 15th, 2020. Routinely-collected clinical and laboratory data were retrospectively retrieved from electronic medical files. A Cox proportional-hazards model was fit to assess the association of treatment and other variables with death.

Results: Median age of patients was 68 years; 150 patients (69%) had comorbidities, mainly hypertension (107, 49%). Overall, 185 (85%) patients had acute respiratory distress syndrome (ARDS) on admission, including 103 (47%) with moderate or severe ARDS. Chest computed tomography scan showed bilateral disease in 201 (98%) and extensive lung involvement in 79 (50%) patients. Most patients received antiviral treatment (187, 86%) and corticosteroids (134, 61%). All patients received respiratory support and 64 (29%) were admitted to intensive care unit. As of June 30th, 100 patients (46%) died, 109 patients (50%) were discharged, and 9 patients (4%) were still hospitalized. In multivariable Cox analysis, age above 65 years, having more than one comorbidity, severe ARDS, low platelet counts, and high LDH levels at admission were associated with mortality, while having diarrhea at admission was associated with survival. The use of antivirals or corticosteroids was not associated with survival.

* Corresponding author: Laboratoire de Bacteriologie-Hygéne, Faculté de Médecine Sorbonne Université, 91 Boulevard de l’hôpital, 75634 Paris Cedex 13, France
E-mail addresses: lorenzo.guglielmetti@aphp.fr (L. Guglielmetti), ikontsevaya@fz-borstel.de (I. Kontsevaya), M.Leoni2@ausl.pc.it (M. Leoni), P.Ferrante@ausl.pc.it (P. Ferrante), E.Fronti@ausl.pc.it (E. Fronti), L.Gerna@ausl.pc.it (L. Gerna), C.Valdatta@ausl.pc.it (C. Valdatta), a.donisi@ausl.pc.it (A. Donisi), A.Faggi@ausl.pc.it (A. Faggi), F.Paolillo@ausl.pc.it (F. Paolillo), G.Ratti@ausl.pc.it (G. Ratti), A.Ruggieri@ausl.pc.it (A. Ruggieri), M.Scotti@ausl.ic.it (M. Scotti), D.Sacchini@ausl.ic.it (D. Sacchini), gloria.taliani@uniroma1.it (G. Taliani), m.codeluppi@ausl.ic.it (M. Codeluppi).
1 Senior authors contributed equally to this study.
2 Members of the COVID-Piacenza Group are the following: Mario Barbera, Francesco Calabrese, Luigi Cavanna, Andrea Magnacavallo, Carlo Moroni, Massimo Noli, Massimo Piepoli, Roberto Schiavo, Matteo Silva. Affiliations for all members is: Piacenza Hospital, Piacenza, Italy.

https://doi.org/10.1016/j.jiph.2020.11.012
1876-0341/© 2020 The Authors. Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction

Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), detected for the first time in Wuhan, China, in December 2019. COVID-19 is thought to have a favorable clinical course in most patients. However, in some cases, it may lead to severe pneumonia and eventually to acute respiratory distress syndrome (ARDS) [1]. To date, there is no established antiviral treatment for COVID-19. Many drugs are currently under investigation, while several are being employed in off-label use, and others are available via compassionate use or expanded access programs. 

As of October 31st, 2020, 45,667,780 cases of COVID-19 and 1,189,499 deaths have been reported worldwide [2], with 594,472 cases and 37,781 deaths having occurred in Italy [3]. Italy, the first Western country reporting sustained COVID-19 transmission, has been disproportionately affected by the epidemic [4–6]. In areas of Northern Italy surrounding the first COVID-19 cluster in the town of Codogno, public healthcare systems have been overwhelmed by the abrupt caseload increase [7]. Limited availability of ventilatory support in intensive care units (ICUs) of many hospitals prompted the need to implement forms of patient triage. After the first months of the epidemic, the province of Piacenza, the closest to the initial cluster, had the highest COVID-19 death rates per population in the country [8]. In the Piacenza Hospital, the first proven case was reported on February 21st, 2020 [9]. As ICU capacity was quickly exhausted by COVID-19 patients, non-ICU medical departments, and in particular the Infectious Diseases Unit, had to admit increasing numbers of critically-ill patients who needed advanced respiratory support.

Multiple case series of COVID-19 patients have been published, mostly from China and the United States [10–18]. However, descriptions of the characteristics of patients in Italy are less common, excluding studies from the ICU setting [19,20]. Moreover, there is a need to characterize management and outcomes of severe cases admitted to non-ICU wards.

In this study, we present the characteristics of patients with severe COVID-19 pneumonia who were admitted to four medical departments of the Hospital of Piacenza during the first epidemic wave of the outbreak, aiming to describe treatment, case fatality rates, and factors associated with mortality.

Materials and methods

Study population and oversight

Consecutive patients admitted to four non-ICU medical departments (Infectious Diseases, Emergency Medicine, and two COVID-19 Units created during the epidemic) of the “Guglielmo da Saliceto” Hospital in Piacenza between February 21st, 2020, and May 15th, 2020, were included in this single-center, retrospective, observational study. Inclusion criteria for the study were the following: (1) confirmed COVID-19 cases with positive Sars-CoV-2 polymerase-chain-reaction (PCR) test, or suspect COVID-19 cases with highly suggestive radiologic evidence on chest high-resolution computed tomography (HRCT), in the absence of an alternative diagnosis, and (2) severe COVID-19 pneumonia. Children (<18 years old) were not included. The study was approved by the local Ethics Committee (Area Vasta Emilia Nord). Requirement for informed consent was waived by the Ethics Committee.

Study definitions

Confirmed and suspect COVID-19 cases, and cases with severe COVID-19 pneumonia were defined according to WHO criteria [21,22]. Confirmed COVID-19 cases were defined as patients with a positive PCR test for SARS-CoV-2. Suspect COVID-19 cases were defined as patients with acute respiratory illness, chest HRCT evidence of lesions compatible with COVID-19, and residence in an area reporting community transmission of COVID-19 disease during the 14 days prior to symptom onset. Severe COVID-19 pneumonia was defined as pneumonia with oxygen saturation on room air of 93% or less at hospital admission.

Study procedures

COVID-19 cases were confirmed using reverse transcriptase real-time PCR on nasopharyngeal swab specimen. HRCT scans were routinely performed at hospital admission to diagnose pulmonary COVID-19 and to assess the extent of lung involvement. HRCT scans were read by expert radiologists, who assessed optically the proportion of lung parenchyma involved by viral pneumonia (i.e. interstitial involvement, ground-glass opacities, crazy-paving pattern, etc.), as described previously [23]. Blood tests (including blood gas testing) were performed at the Clinical Laboratory of the Piacenza Hospital. Results from samples collected on admission or on the following day were considered as baseline results and included in the analysis.

Data collection

Routinely-collected data were retrieved retrospectively from electronic medical files, cross-checked and collated in an anonymized database. Collected data included demographic and clinical characteristics of patients, laboratory and radiologic examinations, treatment and oxygen support received, and outcomes. Treatment data were only available for the period of hospital stay at the medical departments, but not during the stay in the ICU. Data collection was completed and data were locked on June 30th, 2020.

Statistical analysis

Results of continuous data were reported as median and interquartile range (IQR), while categorical data were reported as counts and proportions. Missing data were not imputed. Survival analysis was performed to describe the time from hospitalization to death and Kaplan-Meier curves were estimated for probability of survival after hospitalization, overall and by various strata. Tests between strata were done by the log-rank test. The association of explanatory variables (patient characteristics, symptoms, comorbidities, laboratory and radiologic exams, and treatments) with death was analyzed using a multivariate Cox proportional hazards model. Variables were initially included into the multivariate Cox proportional hazards model if they predicted the outcome at

Conclusions: Overall case fatality rates were high and associated with comorbidities, extensive lung involvement, ARDS at admission, and advanced age. The use of antivirals was not associated with increased survival.
Pulmonary disease was reported in 23 patients: chronic obstructive pulmonary disease (COPD) in 17 (8%) and bronchial asthma in 6 patients (3%). Other reported comorbidities included chronic kidney (20 patients, 9%) and liver (3 patients, 2%) disease, cerebrovascular disease (16 patients, 7%), solid cancer (17 patients, 8%), HIV infection (2 patients, 1%), and iatrogenic immunosuppression (5 patients, 2%).

Virology, radiology, and laboratory results on admission

As shown in Table 2, 216 (99%) patients had a positive PCR for SARS-CoV-2 from a nasopharyngeal swab. Two patients tested negative on admission, but had a HRCT scan showing bilateral interstitial disease and clinical and epidemiological history which was suggestive of COVID-19. The test could not be repeated since these patients died in the first day after admission. All 206 patients with available chest HRCT scan performed on hospital admission had signs of interstitial lung disease, 201 (98%) of them with bilateral involvement. The median proportion of lung parenchyma affected by viral pneumonia was 48% (IQR, 30–60; range, 5–90%), with 79 patients (50%) having extensive lung disease, defined as 50% or more of lung parenchyma affected. Twenty-five (12%) patients had pleural effusion. All patients had blood oxygen saturation of 93% or less on room air on admission. Arterial blood gas analysis found that 33 (15%) patients had an arterial oxygen partial pressure/fractional inspired oxygen (PaO2/FiO2) ratio higher than 300 mmHg, 82 patients (38%) had 200–300 mmHg, 50 patients (23%) had 100–200 mmHg, and 53 patients (24%) had less than 100 mmHg, corresponding to no ARDS, mild ARDS, moderate ARDS, and severe ARDS, respectively. Results of the baseline blood tests are shown in Table 2. Compared to reference values, median values of lymphocyte counts were decreased, while prothrombin time, lactate dehydrogenase, ferritin, C-reactive protein, D-dimer, and interleukin-6 were increased.

Treatment and respiratory support

Table 3 summarizes the treatment received by patients. Most patients (187, 86%) received antiviral treatment and 169 (78%) received a combination of two or more antivirals. Median time from onset of symptoms to the initiation of antiviral treatment was 8 days (IQR, 6–10 days); median duration of antiviral treatment was 6 days (IQR, 3–9 days). Overall, 181 patients (83%) received hydroxychloroquine, 118 patients (54%) received darunavir/ritonavir, 92 patients (42%) received lopinavir/ritonavir, and 5 patients (2%) received remdesivir. Additionally, 134 patients (61%) received corticosteroids. Median time from first symptoms to start of corticosteroid treatment was 10 days (IQR, 8–13 days) with a median treatment duration of 6 days (IQR, 3–10 days). Azithromycin was used as part of large-spectrum antibiotic treatment in 149 patients (68%), and tocilizumab was given to 14 patients (6%). Low molecular weight heparin was administered to 172 patients (79%) at a prophylactic dose and to 20 patients (9%) at a higher dose. Overall, 60 patients (28%) received ACE inhibitors, sartan, or both, for the treatment of hypertension. During hospitalization, all patients were administered respiratory support. Table 3 shows the highest level of respiratory support which was provided: any among nasal cannula, Venturi mask, or mask with reservoir for 58 patients (27%); high-flow nasal cannula for 14 patients (6%); non-invasive ventilation support with continuous positive airway pressure helmets for 88 patients (40%); tracheal intubation for 58 patients (27%). Overall, 64 patients (29%) were transferred from the Infectious Diseases ward to ICU; median time from hospitalization to ICU admission was 5 days (IQR, 3–9 days).

### Table 1
Baseline clinical characteristics and comorbidities of 218 patients hospitalized with severe COVID-19 pneumonia.

| Demographic characteristics | n (%) |
|-----------------------------|-------|
| **Sex, male**               | 172 (79) |
| **Age, years, median (IQR) [range]** | 68 (59–76) [19–102] |
| **Clinical presentation at hospital admission** |       |
| Fever                       | 203 (93) |
| Dyspnea                     | 159 (73) |
| Cough                       | 111 (51) |
| Fatigue                     | 36 (17) |
| Diarrhea                    | 41 (19) |
| **Time from symptoms to hospital admission, days, median (IQR)** | 7 (5–10) |
| **Comorbidities**           |       |
| **Metabolic disease**       |       |
| Obesity (BMI > 30)          | 52 (24) |
| Diabetes mellitus           | 46 (21) |
| **Cardiovascular disease**  |       |
| Hypertension                | 107 (49) |
| Other cardiovascular disease | 56 (26) |
| **Cerebrovascular disease** | 16 (7) |
| **Pulmonary disease**       |       |
| COPD                        | 17 (8) |
| Bronchial asthma            | 6 (3) |
| **Cancer**                  |       |
| Solid cancer                | 17 (8) |
| Onco-hematologic cancer     | 10 (5) |
| **Chronic kidney disease**  | 20 (9) |
| **Chronic liver disease**   | 3 (2) |
| **HIV infection**           | 2 (1) |
| **Iatrogenic immunosuppression** | 5 (2) |
| **Number of comorbidities** |       |
| None                        | 68 (31) |
| One                         | 59 (27) |
| More than one               | 91 (42) |
| Total number, median (IQR)  | 1 (0–4) |

IQR = interquartile range; BMI = body mass index; COPD = chronic obstructive pulmonary disease; HIV = human immunodeficiency virus.

### Table 2
Selected laboratory results on admission

| Test                                | Median (IQR) |
|-------------------------------------|--------------|
| Hemoglobin                          | 10.3 (9.5–11.3) |
| Platelet count                      | 232 (178–308) |
| Prothrombin time                    | 10.6 (8.7–12.7) |
| Lactate dehydrogenase               | 0.8 (0.6–1.1) |
| C-reactive protein                  | 1.2 (0.9–1.6) |

### Table 3
Treatment received by patients.

| Treatment                                      | n (%) |
|------------------------------------------------|-------|
| Antiviral treatment                            | 187 (86) |
| Combination of two or more antivirals          | 169 (78) |
| Antiviral treatment for 8 days                 | 203 (93) |
| Duration of antiviral treatment                | 159 (73) |
| Corticosteroids                                | 149 (68) |
| Azithromycin                                   | 134 (61) |

### Results

Overall, 245 proven or suspect COVID-19 cases were admitted to the four non-ICU medical departments of the Piacenza Hospital during the study period, out of which 218 had severe COVID-19 pneumonia and were included in the study.

### Demographic characteristics of the patients

Baseline clinical characteristics are shown in Table 1. Median age of admitted patients was 68 years (IQR, 59–76; range, 19–102 years); 172 (79%) patients were male. Median time from first symptoms to hospital admission was 7 days (IQR, 5–10 days). Fever (203 patients, 93%), dyspnea (159 patients, 73%), and cough (111 patients, 51%) were the most common symptoms followed by fatigue (36 patients, 17%) and diarrhea (41 patients, 19%). One hundred and fifty patients (69%) had comorbidities with more than half of them (91 patients, 42%) having more than one known comorbidity. The most common comorbidity was hypertension (107 patients, 49%), followed by other cardiovascular diseases (56 patients, 26%), obesity (52 patients, 24%), and diabetes mellitus (46 patients, 21%).

A p-value ≤ 0.20 in univariate analysis and if they fulfilled the proportional hazards assumption; a stepwise backwards hierarchical approach was used for variable selection in the multivariable model. Hazard ratios (HRs) were reported with standard errors and 95%-confidence intervals (CI). No routine imputation of missing explanatory variables was done.

Statistical analysis was performed using Stata software version 15.0 (StataCorp).
Table 2
Baseline diagnostic test results of 218 patients hospitalized with severe COVID-19 pneumonia.

| Test                                      | n (%) | N with available results |
|-------------------------------------------|-------|--------------------------|
| Positive PCR for SARS-CoV-2               | 216 (99) | 218                      |
| Respiratory impairment at hospital admission |     |                          |
| Oxygen saturation ≤93%                    | 218 (100) | 218                      |
| Arterial blood gas test                   |       |                          |
| PaO2/FIO2 ≥ 300 mmHg                      | 33 (15) | 218                      |
| PaO2/FIO2 200 and < 300 mmHg              | 82 (38) | 218                      |
| PaO2/FIO2 > 100 and < 200 mmHg            | 50 (23) | 218                      |
| PaO2/FIO2 < 100 mmHg                      | 53 (24) | 218                      |
| Chest HRCT scan at hospital admission     |       |                          |
| Any interstitial lung disease             | 206 (100) | 206                      |
| Bilateral lung involvement                | 201 (98) | 206                      |
| Proportion of affected lung parenchyma (visual assessment), %, median (IQR) [range] | 48 (30–60) [5–90] | 158                      |
| Extended lung involvement ≤50%            | 79 (50) | 158                      |
| Any pleural effusion                      | 25 (12) | 206                      |
| Blood laboratory test, unit (reference range) |     |                          |
| Hematologic                               |       |                          |
| White blood cells, × 10^3/μL, median (IQR) [4–10] | 7.5 (6.0–9.8) | 218                      |
| Hemoglobin, g/dl, median (IQR) [13–17]    | 13.6 (12.2–14.8) | 218                      |
| Platelets, × 10^3/μL, median (IQR) [150–450] | 197 (157–265) | 218                      |
| Lymphocytes, × 10^3/μL, median (IQR) [1.5–4] | 0.84 (0.62–1.11) | 218                      |
| Biochemistry                              |       |                          |
| Blood creatinine, mg/dl, median (IQR) [0.6–1.2] | 0.99 (0.83–1.25) | 218                      |
| Total bilirubin, mg/dl, median (IQR) [0–1.1] | 0.67 (0.51–0.90) | 206                      |
| Prothrombin time, INR, median (IQR) [0.8–1.1] | 1.29 (1.20–1.37) | 207                      |
| Partial thromboplastin time, ratio, median (IQR) [0.8–1.2] | 0.97 (0.89–1.05) | 123                      |
| Lactate dehydrogenase, U/L, median (IQR) [0–248] | 440 (325–574) | 207                      |
| Ferritin, ng/ml, median (IQR) [12–300]    | 1033 (488–1991) | 92                       |
| C-reactive protein, mg/dl, median (IQR) [0–0.5] | 13.0 (7.7–18.8) | 218                      |
| Procalcitonin, ng/ml, median (IQR) [<0.5]  | 0.38 (0.16–0.92) | 100                      |
| D-dimer, ng/ml, median (IQR) [≤500]       | 1277 (733–4947) | 55                       |
| Interleukin-6, pg/ml, median (IQR) [≤64]   | 64 (13–205) | 40                       |

PCR = polymerase chain reaction; IQR = interquartile range; HRCT = high resolution computed tomography; PaO2 = arterial partial oxygen pressure; FIO2 = fractional inspired oxygen; INR = international normalized ratio.

Outcomes

As of June 30th, 2020, 209 (96%) out of 218 patients had a treatment outcome (Table 3). A total of 100 patients (46%) died, 93 (43%) within 28 days after admission to the hospital. Overall, 68 (31%) died in the ward and 33 (15%) in ICU. Fig. 1 shows Kaplan–Meier curves for mortality, overall and stratified by age (log-rank, p < 0.0001), extension of lung parenchyma affected by pneumonia at chest HRCT scan (log-rank, p < 0.0001), and PaO2/FIO2 ratio on admission (log-rank, p < 0.0001). One hundred-nine patients (50%) were discharged to a rehabilitation facility or sent home. Among these patients, median duration of hospitalization was 18 days (IQR, 11–27 days). Four patients (2%) were still in ICU and 5 patients (2%) were still in a non-ICU ward. Fig. 2 summarizes the time course of disease and treatment history of patients, stratified across four different groups according to final outcome (death or discharge) and to admission to ICU.

Association of treatment and other variables with mortality

Table 4 shows the results of multivariable Cox proportional-hazards model analysing the association of explanatory variables with death. Overall, the following variables were independently associated with death: age above 65 years at admission (HR 4.08; 95% CI 2.37–7.03), more than one comorbidity (HR 1.84; 95% CI 1.04–3.26), severe ARDS at admission (HR 3.66; 95% CI 1.47–9.07), platelet count < 197 × 10^3/μL at admission (HR 2.23; 95% CI 1.42–3.48), and LDH > 440 U/L at admission (HR 1.98; 95% CI 1.19–3.29). Diarrhea at admission was associated with survival (HR 0.31; 0.13–0.72). Of note, antiviral treatment was not associated with increased survival, regardless of whether different drugs were entered as individual variables (hydroxychloroquine: HR 0.65; 95% CI 0.33–1.30; lopinavir/ritonavir: HR 0.66; 95% CI 0.41–1.08; darunavir/coibisatart: HR 0.62; 95% CI 0.37–1.06) or grouped as a single variable (antiviral treatment: HR 0.81; 95% CI 0.43–1.53). Corticosteroid use was associated with survival and included in the final model, although the association did not reach statistical significance (HR 0.72; 95% CI 0.46–1.14).

Discussion

We hereby report high case fatality rates in patients affected by severe COVID-19 pneumonia who were hospitalized in non-ICU wards in Italy, despite the frequent use of antiviral drugs and access to non-invasive ventilation support.

In our study, 79% of patients were male, similar to what has been described for ICU patients in Italy [20]. Overall, 85% of patients in our study had ARDS on admission, including 47% with moderate or severe ARDS. These rates of ARDS, much higher than in previous studies with a similar setting [10,17,18,24], are more comparable to ICU cohorts [11,12,16,20,25], and may account for the high mortality observed in our study (Fig. 1d). The median time from onset of symptoms to hospitalization was 7 days, suggesting that our patients developed severe illness in a short time. Median age was 68 years, which is higher compared to studies from Italy [20], China [10,13,15,24,25], Singapore [26], and the United States [11,12,14], and to surveillance data from Italy [3]. In addition, 69% of patients had at least one comorbidity, which is consistent with data from an ICU-based study from Italy [20], higher than in studies from China [10,13,17,18], although notably lower than in a cohort from the United States [14]. As in previous reports, the most common comorbidities were cardiovascular and metabolic diseases. Therefore, our observation confirms that older age (Fig. 1b) and comorbidities are associated with poor outcomes [16–18,24,27,28]. Another relevant finding was that, among patients who underwent HRCT on admission, half had 50% or more of lung parenchyma affected and 98%
had bilateral disease. It has been shown that the score of pulmonary involvement is associated with ICU admission/death [23] and the results from our study support this conclusion, as well as the routine use of HRCT to assess the extension of pulmonary COVID-19 at hospital admission (Fig. 1c). On clinical grounds, almost all patients had fever, often associated with respiratory symptoms, while gastrointestinal symptoms were present in a minority of patients. This is in line with previous reports [10,12,24,26].

On admission, most patients had reduced lymphocyte counts and an increase in laboratory markers linked to inflammation, such
as lactate dehydrogenase, ferritin, C-reactive protein, Dimer, and interleukin-6. These findings are consistent with previous studies indicating the decrease of antiviral immune response and the trigger of the cytokine storm [10,13,14,24,28].

The vast majority of patients included in the study received at least one antiviral and most of them a combination of two, usually hydroxychloroquine and a boosted protease inhibitor (lopinavir/ritonavir or darunavir/cobicistat). In addition, 61% of patients were treated with corticosteroids. These high rates of treatment were based on local guidelines [29] and understandable in light of the clinical severity at presentation. To date, however, the evidence backing the efficacy of these drugs is limited. In two randomized controlled trials, lopinavir/ritonavir failed to show efficacy compared to standard-of-care [30,31]. The in vivo activity of hydroxychloroquine against COVID-19, despite high expectations, has not been confirmed in a large randomized, controlled clinical trial [32]. In our study, the use of these antivirals, often administered in combination, was not associated with increased survival, reinforcing the strong reserves on the efficacy of these drugs for treatment of severe COVID-19 pneumonia [33]. Corticosteroids are currently a mainstay of treatment of severe COVID-19 pneumonia: while no benefit had been found in the treatment of other coronaviruses [34], multiple randomized, controlled trials have shown that corticosteroids improve survival rates in patients who need oxygen support for COVID-19 [35]. More promising agents like remdesivir [36] and tocilizumab [37] were prescribed to small numbers of patients and could not be assessed in this study. In our study, corticosteroid use was associated with survival, but this finding did not reach statistical significance. This may be partially explained by the heterogeneous timing of start and duration of treatment with corticosteroids in our cohort, and by the small sample size.

The main finding from our study is an overall case fatality rate of 46%, similar to rates reported for ICU patients [11,12,16,20,25] and much higher than those reported in studies from non-ICU wards [10,13–15,24,26]. Mortality rates are often difficult to compare between these two groups of studies, also because indications for intensive care and mechanical ventilation may change greatly among different settings [38]. Indeed, most of our patients have characteristics that would have made them likely eligible for ICU directly at the triage level, had there not been a request overload due to the epidemic wave. Most deaths occurred quickly, half in the first 7 days of hospitalization and the majority within the first 28 days (Fig. 1A). There are multiple possible explanations for the high case fatality rate we observed. Above all, the characteristics of patients in our study are similar to those of ICU cohorts: high rates of comorbidities, extensive lung involvement, high proportion of ARDS at admission, and advanced age – all factors associated with mortality. As a matter of fact, during the peak of the epidemic in Piacenza Hospital, COVID–19 patients who needed ventilatory support were often allocated to non-ICU wards, like the Infectious Diseases or Emergency Medicine Units, which acted as a de facto sub-intensive care ward. This study describes the first wave of the epidemic, including the peak of COVID–19 admissions, and it is remarkable how non-ICU wards were quickly transformed to cope with the emergency, indicating a virtuous learning curve. Indeed, a high proportion of patients in our case series died without being admitted to the ICU, similarly to what has been reported previously in China [39], likely reflecting the lack of ICU resources. Finally, it

Table 3
Treatment, respiratory support received, and outcomes by June 30th, 2020, of 218 patients hospitalized with severe COVID-19 pneumonia.

| Treatment | n (%) |
|-----------|-------|
| **Antivirals** | | 
| Any antiviral | 187 (86) |
| Combination of more than one antiviral | 169 (78) |
| Time from symptoms to antiviral treatment start, days, median (IQR) (N = 187) | 8 (6–10) |
| **Antiviral treatment duration, days, median (IQR) (N = 187)** | | 
| Hydroxychloroquine | 6 (3–9) |
| Darunavir/cobicistat | 181 (83) |
|Lopinavir/ritonavir | 118 (54) |
|Remdesivir | 92 (42) |
| **Corticosteroids** | | 
| Any corticosteroid | 134 (61) |
| Time from symptoms to corticosteroid treatment start, days, median (IQR) (N = 134) | 10 (8–13) |
| Corticosteroid treatment duration, days, median (IQR) (N = 134) | 6 (3–10) |
| **Others** | | 
| Azithromycin | 149 (68) |
| Tocilizumab | 14 (6) |
| Low molecular weight heparin, prophylaxis | 172 (79) |
| Low molecular weight heparin, high dose | 20 (9) |
| **Respiratory support** | | 
| Highest level of respiratory support during hospitalization | | 
| Nasal cannula | 58 (27) |
| Venturi mask, mask with reservoir | 14 (6) |
| High-flow nasal cannula | | 
| CPAP helmet | 88 (40) |
| Tracheal intubation | 58 (27) |
| **ICU** | | 
| Total admitted to ICU | 64 (29) |
| Time from hospital admission to ICU admission, days, median (IQR) (N = 64) | 5 (3–9) |
| **Outcomes** | | 
| **Death** | | 
| Total | 100 (46) |
| At day 28 after hospital admission | 93 (43) |
| Time from hospital admission to death, days, median (IQR) (N = 100) | 8 (5–17) |
| **Discharge from hospital (home or rehabilitation facility)** | | 
| Total | 109 (50) |
| Time from hospital admission to discharge, days, median (IQR) (N = 109) | 18 (11–27) |
| **Outcome not assigned** | | 
| Total | 9 (4) |
| Still in ICU at data lock | 4 (2) |
| Still in hospital at data lock | 5 (2) |

IQR = interquartile range; CPAP = continuous positive airway pressure; ICU = intensive care unit.

* This table summarizes treatment received before and during admission at the medical departments (i.e. it does not include treatment received in the Intensive Care Unit).

Table 4
Association of treatment and other variables with death, assessed using a multivariable Cox proportional-hazards model (N = 218).

| Variables | Hazard ratio | 95% confidence interval | P value |
|-----------|--------------|-------------------------|---------|
| Age >65 years at admission | 4.08 | 2.37–7.03 | <0.001 |
| Diarrhea at admission | 0.31 | 0.13–0.72 | 0.007 |
| More than one comorbidity | 1.84 | 1.04–3.26 | 0.036 |
| Severe ARDS at admission | 3.66 | 1.47–9.07 | 0.005 |
| Platelet count <197 × 10^9/μL at admission | 2.23 | 1.42–3.48 | <0.001 |
| LDH >440 U/L at admission | 1.98 | 1.19–3.29 | 0.008 |

Model adjusted by sex, presence of bilateral disease at computed tomography scan, and treatment with corticosteroids. LDH = lactate dehydrogenase; ARDS = acute respiratory distress syndrome.
has been postulated that high pollution levels in the area may have increased fatality rates in Northern Italy [40] — an element which deserves future research.

This study has multiple limitations. As described above, the specific epidemic circumstances and patient selection must be taken into account. These findings may therefore not be representative of the overall characteristics and outcomes of COVID-19 cases in Piacenza and of severe COVID-19 pneumonia in general. In addition, 4% of patients were still hospitalized, without a final outcome, at data lock. Finally, the retrospective nature of the study explains the high rates of missing information for some laboratory tests.

In conclusion, this study describes the features of patients with severe COVID-19 pneumonia, their outcomes, and factors associated with mortality. These results warn about the consequences of hospital admission of large fluxes of patients that may overwhelm the healthcare system, despite swift response and optimal use of available resources. It seems therefore paramount to implement adequate prevention policies, while optimizing hospital preparedness, and increasing the capacities of medical and ICU wards for the management of future pandemic waves. Our results also highlight the dire need for an effective antiviral treatment for COVID-19 pneumonia. Hopefully, forthcoming randomized controlled clinical trials (NCT04315948, NCT04330690) will allow identifying promising treatment options.

**Funding**

There is no specific funding to declare for this study. The work of the corresponding author (LG) in the Hospital of Piacenza was supported by the Italian Society of Infectious and Tropical Diseases (SIMIT).

**Competing interests**

None declared.

**Ethics approval**

The study was approved by the local Ethics Committee (Area Vasta Emilia Nord). Requirement for informed consent was waived by the Ethics Committee.

**Availability of data and material**

Data may be made available by contacting directly the corresponding author.

**Author contributions**

LG made a substantial contribution to the conception and design of the work, to the acquisition, analysis and interpretation of data for the work, performed statistical analysis, wrote the manuscript, critically revised the manuscript for important intellectual content, gave final approval of the current version to be published, and agrees to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

IK made a substantial contribution to the analysis and interpretation of data for the work, wrote the manuscript, critically revised the manuscript for important intellectual content, gave final approval of the current version to be published, and agrees to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

GT and MC made a substantial contribution to the conception and design of the work, to the analysis and interpretation of data for the work, critically revised the manuscript for important intellectual content, gave final approval of the current version to be published, and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

All other authors gave a substantial contributions to the interpretation of data for the work, revised the manuscript for important intellectual content, gave final approval of the version to be published, and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

**Acknowledgements**

The authors are grateful to the health care workers of the Infectious Diseases Unit, Emergency Medicine department, and the other COVID-19 departments of the “Guglielmo da Saliceto” Hospital in Piacenza, Italy, and to all the patients who were included in the study. A special acknowledgement to Marcello Tavio (Ancona, Italy), Marco Rizzi (Bergamo, Italy), and to the Italian Society of Infectious and Tropical Diseases (SIMIT) for supporting the corresponding author for the work in Piacenza.

**References**

[1] Cheng ZJ, Shan J. 2019 Novel coronavirus: where we are and what we know. Infection 2020;48:155–63, http://dx.doi.org/10.1007/s15010-020-01401-y.

[2] ECDC. Situation update worldwide, as of 31 October 2020. http://www.ecdc.europa.eu/en/geographical-distribution-2019-n cov-cases.nl.

[3] Istituto Superiore di Sanità. Integrated surveillance of COVID-19 in Italy. 30 October 2020 update. https://www.epicenter红楼梦/En/Coronavirus/Sars-Cov-2-Dashboard, [Accessed 31 October 2020]. nl.

[4] Guglielmetti L, Chiesi S. COVID-19 in Italy: passing through bitter waters. Eur Respir J 2020;56(2001812), http://dx.doi.org/10.1183/13993003.01812-2020.

[5] Li C, Romagnani P, von Brunn A, Anders H-J. SARS-CoV-2 and Europe: timing of containment measures for outbreak control. Infection 2020;48:483–6, http://dx.doi.org/10.1007/s15010-020-01420-9.

[6] Fusaroli P, Balena S, Lisotti A. On the death of 100 + Italian doctors from COVID-19. Infection 2020, http://dx.doi.org/10.1007/s15010-020-01436-1.

[7] Pagliudi S, Lorini FL, Romuzzi C. Adaptations and lessons in the province of Bergamo. N Engl J Med 2020, http://dx.doi.org/10.1056/NEJMCl2011599, NEJMc2011599.

[8] Ferrari L, Gerardi G, Manzi G, Michelietti A, Niccolussi F, Salini S. COVID-19 in Italy: an app for a province-based analysis. ArXiv:200412779 [Physics, q-Bio] 2020.

[9] Berté R, Cassinelli D, Vignola V, Bonfanti S, Pagano S, Costa A, et al. Covid-19: The role of palliative care had to be adapted to manage this “ultra-emergency.” The BMJ Opinion Blogs n.d.; https://blogs.bmj.com/bmj/2020/03/31/covid-19-the-role-of-palliative-care-had-to-be-adapted-to-manage-this-ultra-emergency/. [Accessed 3 May 2020].

[10] Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020, http://dx.doi.org/10.1056/NEJMoa2002032, NEJMoa2002032.

[11] Arentz M, Yim E, Klaff L, Lokhandwala S, Riedo FX, Chong M, et al. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State. JAMA 2020, http://dx.doi.org/10.1001/jama.2020.4326.

[12] Bhatraju PK, Chassamieh BJ, Nichols M, Kim R, Jerome KR, Nallak AK, et al. COVID-19 in critically ill patients in the Seattle region — case series. N Engl J Med 2020, http://dx.doi.org/10.1056/NEJMoa2004500, NEJMoa2004500.

[13] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497–506, http://dx.doi.org/10.1016/S0140-6736(20)30183-5.

[14] Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McCinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area. JAMA 2020, http://dx.doi.org/10.1001/jama.2020.6775.

[15] Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–Infected pneumonia in Wuhuan, China. JAMA 2020;323:1061, http://dx.doi.org/10.1001/jama.2020.1585.

[16] Wang Y, Lu X, Chen H, Chen T, Su N, Huang F, et al. Clinical course and outcomes of 344 intensive care patients with COVID-19. Am J Respir Crit Care Med 2020, http://dx.doi.org/10.1164/rccm.202003-0736EL.

[17] Chen Q, Zheng Z, Zhang C, Zhang X, Wu H, Wang, et al. Clinical characteristics of 145 patients with corona virus disease 2019 (COVID-19) in Taizhous, Zhejiang, China. Infection 2020, http://dx.doi.org/10.1007/s15010-020-01432-5.
[18] Zhang H, Shang W, Liu Q, Zhang X, Zheng M, Yue M. Clinical characteristics of 194 cases of COVID-19 in Huanggang and Taimen, China. Infection 2020; http://dx.doi.org/10.1007/s15010-020-01440-5.

[19] Grasselli G, Pesenti A, Cecconi M. Critical care utilization for the COVID-19 outbreak in Lombardy, Italy: early experience and forecast during an emergency response. JAMA 2020;323:1154–6, http://dx.doi.org/10.1001/jama.2020.4031.

[20] Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA 2020, http://dx.doi.org/10.1001/jama.2020.5394.

[21] WHO. Global surveillance for COVID-19 caused by human infection with COVID-19 virus. Interim guidance. 20 March 2020. WHO/2019-NCov/SurveillanceGuidance2020V.E2.d.

[22] WHO. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected. Interim guidance. 13 March 2020. WHO/2019-NCov/Clinical2020V.E2.d.

[23] Colombo D, Bodini FC, Pettrini M, Maffi G, Morelli N, Milanese G, et al. Well-aerated lung on admitting chest CT to predict adverse outcome in COVID-19 pneumonia. Radiology 2020;201433, http://dx.doi.org/10.1148/ radiol.2020201433.

[24] Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054–62, http://dx.doi.org/10.1016/S0140-6736(20)30566-2.

[25] Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020;22:1126002020300759, http://dx.doi.org/10.1016/S2213-2600(20)30079-5.

[26] Young BE, Ong SWX, Kalimuddin S, Low JG, Tan SY, Loh J, et al. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. JAMA 2020;323:1488, http://dx.doi.org/10.1001/jama.2020.1204.

[27] Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020, http://dx.doi.org/10.1001/jamainternmed.2020.0994.

[28] Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 2020, http://dx.doi.org/10.1136/bmj.m1091, m1091.

[29] Lombardy Section Italian Society Infectious and Tropical Diseases. Vademecum for the treatment of people with COVID-19. Edition 2.0, 13 March 2020. Infez Med 2020;28:143–52.

[30] Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of lopinavir–ritonavir in adults hospitalized with severe covid-19. N Engl J Med 2020, http://dx.doi.org/10.1056/NEJMoa2001282.

[31] Horby PW, Maflham M, Bell JL, Linsell L, Staplin N, Emerson J, et al. Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 2020;396:1345–52, http://dx.doi.org/10.1016/S0140-6736(20)30134-4.

[32] Horby P, Maflham M, Linsell I, Bell JL, Staplin N, Emerson JR, et al. Effect of Hydroxychloroquine in hospitalized Patients with COVID-19: preliminary results from a multi-centre, randomized, controlled trial. MedRxiv 2020;20151852, http://dx.doi.org/10.1101/2020.07.15.20151852.

[33] Waterer GW, Rello J, Wunderink RG. SARS-CoV-2: first do No harm. Am J Respir Crit Care Med 2020, http://dx.doi.org/10.1164/rccm.202004-1153ED.

[34] Aba Y, Mandourah Y, Al-Hameed F, Sindii AA, Almekhlafi GA, Hussein MA, et al. Corticosteroid therapy for critically ill patients with middle east respiratory syndrome. Am J Respir Crit Care Med 2018;197:757–67, http://dx.doi.org/10.1164/rccm.201706-1172OC.

[35] Group TWREA for C-19 T. (REACT) W, Sterne JAC, Murphy S, Daz N, Slutzky AS, Villar J, et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA 2020, http://dx.doi.org/10.1001/jama.2020.17023.

[36] Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of COVID-19 — preliminary report. N Engl J Med 2020;0, http://dx.doi.org/10.1056/NEJMoa2007764, null.

[37] Hermine O, Mariette X, Tharaux P-L, Resche-Rigon M, Porcher R, Ravaud P, et al. Effect of Tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial. JAMA Intern Med 2020, http://dx.doi.org/10.1001/jamainternmed.2020.6820.

[38] Wunsch H, Mechanical ventilation in COVID-19: interpreting the current epidemiology. Am J Respir Crit Care Med 2020, http://dx.doi.org/10.1164/rccm.202004-1385ED.

[39] Xie J, Tong Z, Guan X, Du B, Qiu H. Clinical characteristics of patients who died of coronavirus disease 2019 in China. JAMA Netw Open 2020;3:e2005619, http://dx.doi.org/10.1001/jamanetworkopen.2020.5619.

[40] Setti L, Passarini F, De Gennaro G, Barbieri P, Perrone MG, et al. SARS-cov-2 RNA found on particulate matter of Bergamo in Northern Italy: first preliminary evidence. Infect Dis (Except HIV/AIDS) 2020, http://dx.doi.org/10.1101/2020.04.15.20065995.